GAINESVILLE, Fla., April 8, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it will present its latest work on an innovative new wound dressing that incorporates its unique and proprietary NIMBUS technology at the 2011 Symposium on Advances in Wound Care / Wound Healing Society meeting. This event is the premier meeting of physicians, researchers and other wound care specialists and is being held in Dallas, Texas on April 14-17, 2011.
NIMBUS® Advanced Active is the first "active" wound healing product in development by Quick-Med. It is a superabsorbent, non-leaching antimicrobial dressing that provides a moist wound healing environment plus the sustained release of active agents to promote optimum healing of burns and chemical blistering wounds. Specific agents used in this study were a growth factor, an antibiotic protease inhibitor (doxycycline) and antioxidant vitamins C and E.
The comprehensive in vivo animal experiments, which were conducted on half of Quick-Med by Battelle Memorial Institute, found that the NIMBUS-based dressings provided significantly improved wound healing compared to controls. Relative to controls, wounds treated with NIMBUS Advanced Active prototype dressings had more rapid formation of mature and well ordered dermal tissue with no scar tissue generation, and better structural support epidermis. In summary, the NIMBUS dressings show clear signs of better healing.
"The results of this study at Battelle show a dramatic improvement in speed and quality of healing of skin injuries caused by vesicant agents," said Greg Schultz, University of Florida Professor and former President of the Wound Healing Society. "This is an exciting implementation of our platform antimicrobial NIMBUS technology, demonstrating its clinical efficacy in controlling bioburden on wounds and accelerating healing," said Bernd Liesenfeld, Quick-Med's Principal Investigator for the study.
Quick-Med's research and development on this project is being supported by a Small Business Innovation Research (SBIR) grant awarded by the U.S. Army Medical Research and Material Command. NIMBUS was competitively selected by the U.S. Army to develop a wound dressing prototype capable of enhancing the healing of debrided vesicant wounds and other injuries.
About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
About the Symposium on Advances Wound Care / Wound Healing Society
Now in its 24th year, the Symposium is the premier educational wound care program within this clinical field and is one of the largest annual gatherings of wound care clinicians in the United States.
The Wound Healing Society is a non-profit organization composed of clinical and basic scientists. Founded in 1990, the Society is recognized among professionals and government agencies as the leading scientific organization focused in the area of wound healing.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at .
CONTACT: Quick-Med Technologies, Inc. Jerry Olderman, Ph.D., VP, R&D (888) 835.2211 Ext 104 jolderman@quickmedtech.com Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121 casey@stonegateinc.com
